Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma [Cancer Immunology, Immunotherapy, 63, (2014) 675-683, DOI 10.1007/s00262-014-1545-8];Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

Cancer Immunology, Immunotherapy

Volumn 63, Issue 7, 2014, Pages 675-683

  Simeone, Ester ^a   Gentilcore, Giusy ^a   Giannarelli, Diana ^b   Grimaldi, Antonio M ^a   Caracò, Corrado ^a   Curvietto, Marcello ^a   Esposito, Assunta ^a   Paone, Miriam ^a   Palla, Marco ^a   Cavalcanti, Ernesta ^a   Sandomenico, Fabio ^a   Petrillo, Antonella ^a   Botti, Gerardo ^a   Fulciniti, Franco ^a   Palmieri, Giuseppe ^c   Queirolo, Paola ^d   Marchetti, Paolo ^e,f   Ferraresi, Virginia ^b   Rinaldi, Gaetana ^g   Pistillo, Maria Pia ^d   Ciliberto, Gennaro ^a   Mozzillo, Nicola ^a   Ascierto, Paolo A ^a   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

Author keywords

Biomarker; Expanded access programme; Immunological; Ipilimumab; Melanoma

Indexed keywords

B RAF KINASE; BINIMETINIB; C REACTIVE PROTEIN; CISPLATIN; CORTICOSTEROID; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; IPILIMUMAB; LACTATE DEHYDROGENASE; LIVER ENZYME; TEMOZOLOMIDE; TRANSCRIPTION FACTOR FOXP3; VEMURAFENIB;

ABSOLUTE LYMPHOCYTE COUNT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; B RAF KINASE GENE; CANCER CONTROL; CANCER SURVIVAL; COMPASSIONATE USE; COOMBS TEST; DIARRHEA; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MUTATIONAL ANALYSIS; NEUTROPENIA; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PRURITUS; RASH; REGULATORY T LYMPHOCYTE; RETICULOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; EYE NEOPLASMS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903818245     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1611-2     Document Type: Erratum

References (31)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
2. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE et al (2012) CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039-2047
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516
4. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365
5. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P et al (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14:249-256
6. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA et al (2013) Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31:482-489
7. Atkinson AJ, Magnuson WG, Colbern WA, DeGrutolla VG, DeMets DL, Downing GJ et al (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95 (Pubitemid 32225406)
8. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG (2008) Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 44:946-953
9. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA et al (2011) Defining the critical hurdles in cancer immunotherapy. J Transl Med 9:214
10. Menard C, Ghiringhelli F, Roux S, Chaput N, Mateus C, Grohmann U et al (2008) CTLA-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res 14:5242-5249
11. Sarnaik A, Yu B, Yu D, Morelli D, Hall M, Bogle D et al (2011) Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 17:896-906
12. Marshall MA, Ribas A, Huang B (2010) Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma. J Clin Oncol 28: abstr 2609
13. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD et al (2010) Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116:1767-1775
14. Simeone E, Gentilcore G, Romano A, Daponte A, Caraco C, Grimaldi AM, et al (2012) Immunological and Biological Changes During Ipilimumab Treatment and their Correlation with Clinical Response and Survival. J Clin Oncol 30 (suppl). abst 8573
15. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412-7420
16. Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A et al (2010) Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med 8:76
17. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ et al (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534 (Pubitemid 351264344)
18. Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD (2013) Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 19:1009-1020
19. Breunis WB, Tarazona-Santos E, Chen R, Kiley M, Rosenberg SA, Chanock SJ (2008) Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother 31:586-590
20. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J et al (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9:204
21. Wang W, Yu D, Sarnaik A, Yu B, Hall M, Morelli D et al (2012) Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med 10:146
22. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF et al (2011) Integrated NY-ESO-1 antibody and CD8 + T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 108:16723-16728
23. Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N et al (2013) Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 24:1697-1703
24. Di Giacomo AM, Calabro L, Danielli R, Fonsatti E, Bertocci E, Pesce I et al (2013) Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 62:1021-1028
25. Wilgenhof S, Du FS, Vandenbroucke F, Everaert H, Salmon I, Liénard D et al (2013) Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 36:215-222
26. Postow MA, Chasalow SD, Yuan J, Kuk D, Panageas KS, Cheng M et al (2013) Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma. J Clin Oncol 31: abstr 9052
27. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206
28. Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY et al (1996) Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 14:1697-1703 (Pubitemid 26134229)
29. Blank CU, Kelderman S, van Tinteren H, Heemskerk B, van den Brom R, Hospers GA et al (2013) Serum lactate dehydrogenase (LDH) as a prognostic selection criterion for ipilimumab treatment in metastatic melanoma. J Clin Oncol 31: abstr 3036
30. Hotson D, Conroy A, Evensen E, Gentilcore G, Simeone E, Esposito A et al (2012) CTLA-4 defines distinct T cell signaling populations in healthy donors and metastatic melanoma patients. J Immunother 11: abstr 760
31. Ladoire S, Martin F, Ghiringhelli F (2011) Prognostic role of FOXP3 + regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 60:909-918